Performance Cell Manufacturing (PCM), a contract manufacturing organization division of VetStem Biopharma, has joined forces with leading human cancer therapy company, Calidi Biotherapeutics, to collaborate on a potential new cancer treatment. In a patented process, Calidi has discovered how to utilize adipose derived stem cells as a “Trojan horse” to deliver their promising oncolytic virus therapy. Calidi completed the collection of adipose tissue from disease screened human donors, which initiated the next phase of stem cell manufacturing at PCM’s cGMP cell manufacturing facility in Poway, California.
PCM CEO, Dr. Bob Harman stated, “We began working with Calidi several years ago to combine their cutting-edge research with our extensive experience in stem cell manufacturing. This collaboration may prove to be a game-changer in the human medical field, and we are proud to partner with Calidi to help bring this potential cancer therapy to market.”
PCM was born from over 15 years of clinical, regulatory, and manufacturing experience. VetStem received approval from the California Department of Public Health – Food and Drug Branch for manufacturing and has been providing contract cell manufacturing services to companies engaged in human clinical trials since 2018.